TY - JOUR
T1 - Identification of Reduced ERAP2 Expression and a Novel HLA Allele as Components of a Risk Score for Susceptibility to Liver Injury Due to Amoxicillin-Clavulanate
AU - Drug-Induced Liver Injury Network (DILIN)
AU - International Drug-Induced Liver Injury Consortium (iDILIC)
AU - Prospective European Drug-Induced Liver Injury (Pro-Euro DILI) Investigators
AU - Nicoletti, Paola
AU - Dellinger, Andrew
AU - Li, Yi Ju
AU - Barnhart, Huiman X.
AU - Chalasani, Naga
AU - Fontana, Robert J.
AU - Odin, Joseph A.
AU - Serrano, Jose
AU - Stolz, Andrew
AU - Etheridge, Amy S.
AU - Innocenti, Federico
AU - Govaere, Olivier
AU - Grove, Jane I.
AU - Stephens, Camilla
AU - Aithal, Guruprasad P.
AU - Andrade, Raul J.
AU - Bjornsson, Einar S.
AU - Daly, Ann K.
AU - Lucena, M. Isabel
AU - Watkins, Paul B.
N1 - Publisher Copyright:
© 2023 AGA Institute
PY - 2023/3
Y1 - 2023/3
N2 - Background & Aims: Drug-induced liver injury (DILI) due to amoxicillin–clavulanate (AC) has been associated with HLA-A∗02:01, HLA-DRB1∗15:01, and rs2476601, a missense variant in PTPN22. The aim of this study was to identify novel risk factors for AC-DILI and to construct a genetic risk score (GRS). METHODS: Transcriptome-wide association study and genome-wide association study analyses were performed on 444 AC-DILI cases and 10,397 population-based controls of European descent. Associations were confirmed in a validation cohort (n = 133 cases and 17,836 population-based controls). Discovery and validation AC-DILI cases were also compared with 1358 and 403 non–AC-DILI cases. Results: Transcriptome-wide association study revealed a significant association of AC-DILI risk with reduced liver expression of ERAP2 (P = 3.7 × 10–7), coding for an aminopeptidase involved in antigen presentation. The lead eQTL single nucleotide polymorphism, rs1363907 (G), was associated with AC-DILI risk in the discovery (odds ratio [OR], 1.68; 95% CI, 1.23–1.66; P = 1.7 × 10–7) and validation cohorts (OR, 1.2; 95% CI, 1.04–2.05; P =.03), following a recessive model. We also identified HLA-B∗15:18 as a novel AC-DILI risk factor in both discovery (OR, 4.19; 95% CI, 2.09–8.36; P = 4.9 × 10–5) and validation (OR, 7.78; 95% CI, 2.75–21.99; P =.0001) cohorts. GRS, incorporating rs1363907, rs2476601, HLA-B∗15:18, HLA-A∗02:01, and HLA-DRB1∗15:01, was highly predictive of AC-DILI risk when cases were analyzed against both general population and non–AC-DILI control cohorts. GRS was the most significant predictor in a regression model containing known AC-DILI clinical risk characteristics and significantly improved the predictive model. Conclusions: We identified novel associations of AC-DILI risk with ERAP2 low expression and with HLA-B∗15:18. GRS based on the 5 risk variants may assist AC-DILI causality assessment and risk management.
AB - Background & Aims: Drug-induced liver injury (DILI) due to amoxicillin–clavulanate (AC) has been associated with HLA-A∗02:01, HLA-DRB1∗15:01, and rs2476601, a missense variant in PTPN22. The aim of this study was to identify novel risk factors for AC-DILI and to construct a genetic risk score (GRS). METHODS: Transcriptome-wide association study and genome-wide association study analyses were performed on 444 AC-DILI cases and 10,397 population-based controls of European descent. Associations were confirmed in a validation cohort (n = 133 cases and 17,836 population-based controls). Discovery and validation AC-DILI cases were also compared with 1358 and 403 non–AC-DILI cases. Results: Transcriptome-wide association study revealed a significant association of AC-DILI risk with reduced liver expression of ERAP2 (P = 3.7 × 10–7), coding for an aminopeptidase involved in antigen presentation. The lead eQTL single nucleotide polymorphism, rs1363907 (G), was associated with AC-DILI risk in the discovery (odds ratio [OR], 1.68; 95% CI, 1.23–1.66; P = 1.7 × 10–7) and validation cohorts (OR, 1.2; 95% CI, 1.04–2.05; P =.03), following a recessive model. We also identified HLA-B∗15:18 as a novel AC-DILI risk factor in both discovery (OR, 4.19; 95% CI, 2.09–8.36; P = 4.9 × 10–5) and validation (OR, 7.78; 95% CI, 2.75–21.99; P =.0001) cohorts. GRS, incorporating rs1363907, rs2476601, HLA-B∗15:18, HLA-A∗02:01, and HLA-DRB1∗15:01, was highly predictive of AC-DILI risk when cases were analyzed against both general population and non–AC-DILI control cohorts. GRS was the most significant predictor in a regression model containing known AC-DILI clinical risk characteristics and significantly improved the predictive model. Conclusions: We identified novel associations of AC-DILI risk with ERAP2 low expression and with HLA-B∗15:18. GRS based on the 5 risk variants may assist AC-DILI causality assessment and risk management.
KW - Amoxicillin-Clavulanate
KW - DILI
KW - ERAP2
KW - GWAS
KW - HLA-B∗15:18
UR - http://www.scopus.com/inward/record.url?scp=85147287740&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2022.11.036
DO - 10.1053/j.gastro.2022.11.036
M3 - Article
C2 - 36496055
AN - SCOPUS:85147287740
SN - 0016-5085
VL - 164
SP - 454
EP - 466
JO - Gastroenterology
JF - Gastroenterology
IS - 3
ER -